Belpointe Asset Management LLC Beam Therapeutics Inc. Transaction History

Belpointe Asset Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$30.15 - $48.79 $70,852 - $114,656	-2,350 Reduced 83.19%	475 $14,000
Q4 2022 Feb 08, 2023	SELL	$36.73 - $51.6 $1,836 - $2,580	-50 Reduced 1.74%	2,825 $110,000
Q3 2022 Nov 14, 2022	BUY	$39.79 - $70.31 $114,396 - $202,141	2,875 New	2,875 $137,000
Q2 2022 Aug 02, 2022	SELL	$29.86 - $62.36 $71,664 - $149,664	-2,400 Closed	0 $0
Q1 2022 Apr 28, 2022	SELL	$53.73 - $82.16 $1,880 - $2,875	-35 Reduced 1.44%	2,400 $138,000
Q3 2021 Nov 15, 2021	BUY	$84.37 - $133.6 $674 - $1,068	8 Added 0.33%	2,435 $212,000
Q1 2021 May 14, 2021	BUY	$71.28 - $120.75 $4,847 - $8,211	68 Added 2.88%	2,427 $194,000
Q4 2020 Feb 16, 2021	BUY	$22.24 - $95.63 $52,464 - $225,591	2,359 New	2,359 $193,000

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Belpointe Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Belpointe Asset Management LLC with notifications on news.